Oxford Biomedica PLC (LSE: OXB), the cell and gene therapy contract development and manufacturing organisation (CDMO), has announced an application to the London Stock Exchange for the admission to trading of 430,825 new ordinary shares of 50 pence each. The shares have been allotted under the company's Long Term Incentive Plan and Deferred Bonus Plan. Admission is expected to become effective on 19 November 2026, with the new shares ranking equally in all respects with existing ordinary shares in issue.
Key Points
- Oxford Biomedica PLC (LSE: OXB), a FTSE 250 and FTSE4Good constituent cell and gene therapy CDMO
- Application made to the London Stock Exchange to admit 430,825 new ordinary shares of 50 pence each
- Shares allotted under the OXB Long Term Incentive Plan (LTIP) and Deferred Bonus Plan (DBP); admission expected 19 November 2026
- Investors should watch for confirmation of admission becoming effective and any further employee share scheme activity
430,825 New OXB Shares Issued Under Long Term Incentive and Deferred Bonus Plans
Oxford Biomedica has applied for admission to trading of 430,825 ordinary shares of 50 pence each on the London Stock Exchange. The announcement states that the new shares have been allotted pursuant to two separate employee share schemes: the OXB Long Term Incentive Plan and the OXB Deferred Bonus Plan. These mechanisms are commonly used by listed companies to reward and retain senior employees and management over defined performance periods. Admission is expected to take effect on 19 November 2026, following which the shares will rank pari passu in all respects with Oxford Biomedica's existing ordinary share capital.
New Shares Rank Equally With Existing Oxford Biomedica Ordinary Share Capital
The company confirmed in the announcement that the New Ordinary Shares will rank pari passu with its existing issued ordinary shares, meaning they carry identical rights with respect to dividends, voting, and distributions. This is standard practice when shares are issued under employee incentive schemes. The disclosure represents a modest increase to Oxford Biomedica's total ordinary share count. The company did not disclose the resulting updated total number of shares in issue following this admission in the announcement, which investors may wish to monitor via subsequent regulatory filings.
Oxford Biomedica's Role as a Global Cell and Gene Therapy CDMO
Oxford Biomedica is headquartered in Oxford, UK, and operates development and manufacturing facilities in Oxfordshire, Lyon and Strasbourg in France, and Bedford, Massachusetts and Durham, North Carolina in the United States. The company has more than 30 years of experience in viral vectors and collaborates with leading pharmaceutical and biotechnology companies globally. Its proprietary technologies include the fourth-generation TetraVecta™ lentiviral vector system and dual-plasmid AAV production platforms, supporting projects from early-stage development through to commercial-scale manufacturing.
Employee Share Schemes as an Ongoing Feature of OXB's Remuneration Structure
The use of both a Long Term Incentive Plan and a Deferred Bonus Plan reflects Oxford Biomedica's structured approach to aligning management incentives with shareholder interests over multi-year periods. As a FTSE 250 constituent operating in the capital-intensive cell and gene therapy sector, retaining specialist scientific and commercial talent represents a material operational consideration. Investors may be watching whether further share allotments under these or related schemes are announced in coming months, as the company continues to scale its global CDMO capabilities.




Please wait processing your request...